No Picture
News

Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD(TM) in Models of Colorectal Cancer

ONZEALD is currently being evaluated in a Phase 3 trial in patients with metastatic breast cancer and brain metastases

SAN DIEGO, May 23, 2019 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a pr… […]

No Picture
News

Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

– Triggers $10 million milestone payment to Halozyme in the second quarter –

SAN DIEGO, May 22, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today anno… […]

No Picture
News

Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019

Presentation to Highlight Positive Data Demonstrating Clinical and Biomarker Activity Suggesting Localized Target Engagement and Minimal Systemic Exposure Following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colit… […]

No Picture
News

Heron Therapeutics Partners with the National Academy of Medicine to Counter the Opioid Epidemic in the United States

SAN DIEGO, May 7, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet pa… […]

No Picture
News

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

SAN DIEGO, April 24, 2019 /PRNewswire/ — Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced today that they have entered into a res… […]

No Picture
News

BioAtla Subsidiary, Himalaya Therapeutics, Will Develop And Commercialize CAB Products In Greater China Market

First Conditionally Active Biologics licensing participation in Greater China territory

SAN DIEGO, April 16, 2019 /PRNewswire/ — BioAtla ®, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biolog… […]

No Picture
News

Trianni, Inc. and San Diego Biomedical Research Institute Announce License Agreement for the Trianni Mouse®

SAN FRANCISCO and SAN DIEGO, March 21, 2019 /PRNewswire/ — Trianni, Inc. (“TRIANNI”) and San Diego Biomedical Research Institute (“SDBRI”) jointly announced today that they have entered into a license agreement for the use of the Trianni Mouse®, a … […]

No Picture
News

Biocept and Providence Saint John’s Health Center Collaborate to Evaluate Cerebrospinal Fluid for Use with Liquid Biopsy Testing in Metastatic Cancer

Saint John’s and John Wayne Cancer Institute to validate use of cerebrospinal fluid with the Company’s Target Selector(TM) assay platform in patients with known or suspected brain metastases

SAN DIEGO, Feb. 27, 2019 /PRNewswire/ — Biocept, Inc. (NAS… […]